Cargando…

Real world use of lanreotide in neuroendocrine tumors

BACKGROUND: Treatment for metastatic neuroendocrine tumors (NETs) is often with somatostatin analogues (SSA) such as lanreotide in the first-line setting. Real world use of lanreotide in Canada is not well studied. METHODS: We performed a retrospective chart review of 69 patients to study real world...

Descripción completa

Detalles Bibliográficos
Autores principales:	Siddiqui, Zeba, Marginean, Horia, Leung, Macyn, Asmis, Timothy, Vickers, Michael, Goodwin, Rachel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10331746/ https://www.ncbi.nlm.nih.gov/pubmed/37435213 http://dx.doi.org/10.21037/jgo-22-1182

Ejemplares similares

Small Bowel Neuroendocrine Tumors—10-Year Experience of the Ottawa Hospital (TOH)
por: Alfagih, Abdulhameed, et al.
Publicado: (2023)

Lanreotide Depot: An Antineoplastic Treatment of Carcinoid or Neuroendocrine Tumors
por: Wolin, Edward M., et al.
Publicado: (2016)

Clinical utility of lanreotide Autogel(®) in gastroenteropancreatic neuroendocrine tumors
por: Paragliola, Rosa Maria, et al.
Publicado: (2016)

The Impact of Virtual Cancer Care on Chemotherapy Delivery and Clinical Outcomes in Colorectal Cancer Patients Receiving Systemic Therapy: A Pre- and Intra-Pandemic Analysis
por: Phillips, William J., et al.
Publicado: (2022)

Current treatment options for gastroenteropancreatic neuroendocrine tumors with a focus on the role of lanreotide
por: Kos-Kudła, Beata, et al.
Publicado: (2017)

Lanreotide Induces Cytokine Modulation in Intestinal Neuroendocrine Tumors and Overcomes Resistance to Everolimus
por: Sciammarella, Concetta, et al.
Publicado: (2020)

Predictors of antiproliferative effect of lanreotide autogel in advanced gastroenteropancreatic neuroendocrine neoplasms
por: Laskaratos, Faidon-Marios, et al.
Publicado: (2019)

Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictive and prognostic markers in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiation
por: Dudani, Shaan, et al.
Publicado: (2019)

Long-Term Disease Control of a Pancreatic Neuroendocrine Tumor with Lanreotide Autogel(®): A Case Report
por: Lybaert, Willem, et al.
Publicado: (2014)

Treatment with Lanreotide Depot Following Octreotide Long-Acting Release Among Patients with Gastroenteropancreatic Neuroendocrine Tumors
por: Saif, Muhammad Wasif, et al.
Publicado: (2018)

Lanreotide vs octreotide LAR for patients with advanced gastroenteropancreatic neuroendocrine tumors: An observational time and motion analysis
por: Ryan, P, et al.
Publicado: (2019)

Phase II study of lanreotide autogel in Japanese patients with unresectable or metastatic well-differentiated neuroendocrine tumors
por: Ito, Tetsuhide, et al.
Publicado: (2017)

Long-Term Disease Control of a Non-Operable Neuroendocrine Tumor of the Lung with Lanreotide: A Case Study
por: Van Fraeyenhove, F., et al.
Publicado: (2012)

Multicenter, Observational Study of Lanreotide Autogel for the Treatment of Patients with Neuroendocrine Tumors in Routine Clinical Practice in Germany and Austria
por: Rinke, Anja, et al.
Publicado: (2021)

Lanreotide Depot to Treat Gastroenteropancreatic Neuroendocrine Tumors in a US Community Oncology Setting: A Prospective, Observational Study
por: Paulson, Scott, et al.
Publicado: (2022)

High-Dose Lanreotide in the Treatment of Poorly Differentiated Pancreatic Neuroendocrine Carcinoma: A Case Report
por: Van Fraeyenhove, Frank, et al.
Publicado: (2014)

Phosphorylated transducer and activator of transcription-3 (pSTAT3) immunohistochemical expression in paired primary and metastatic colorectal cancer
por: Marginean, Esmeralda C., et al.
Publicado: (2020)

Assessing the safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic and thoracic neuroendocrine tumors: rationale and protocol of the phase II LOLA trial
por: Corti, Francesca, et al.
Publicado: (2023)

Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study
por: Caplin, Martyn E, et al.
Publicado: (2016)

Effectiveness of self- or partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-naïve patients with acromegaly
por: Salvatori, Roberto, et al.
Publicado: (2009)

Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study
por: Caplin, Martyn E., et al.
Publicado: (2020)

Novel Tumor Growth Rate Analysis in the Randomized CLARINET Study Establishes the Efficacy of Lanreotide Depot/Autogel 120 mg with Prolonged Administration in Indolent Neuroendocrine Tumors
por: Dromain, Clarisse, et al.
Publicado: (2021)

Anomalous dynamics of water at the octopeptide lanreotide surface
por: Pinzan, Florian, et al.
Publicado: (2020)

Randomized crossover study in patients with neuroendocrine tumors to assess patient preference for lanreotide Autogel(®) given by either self/partner or a health care professional
por: Johanson, Viktor, et al.
Publicado: (2012)

Long‐term safety and efficacy of lanreotide autogel in Japanese patients with neuroendocrine tumors: Final results of a phase II open‐label extension study
por: Ito, Tetsuhide, et al.
Publicado: (2020)

Assessment of real-world usage of lanreotide AUTOGEL 120 in Polish acromegalic patients – results from the prospective 12-month phase of Lanro-Study
por: Orlewska, Ewa, et al.
Publicado: (2013)

Co-Creation of a Lanreotide Autogel/Depot Syringe for the Treatment of Acromegaly and Neuroendocrine Tumours Through Collaborative Human Factor Studies
por: Adelman, Daphne T., et al.
Publicado: (2019)

Diabetes Insipidus Induced by Combination of Short-acting Octreotide and Lanreotide for Recurrent Carcinoid Crisis of Neuroendocrine Tumour: A Case Report
por: Guan, Goh Kian, et al.
Publicado: (2021)

Therapeutic options in the management of acromegaly: focus on lanreotide Autogel(®)
por: Roelfsema, Ferdinand, et al.
Publicado: (2008)

Atomic structure of Lanreotide nanotubes revealed by cryo-EM
por: Pieri, Laura, et al.
Publicado: (2022)

The Use of Lanreotide in Polycystic Kidney Disease: A Single-Centre Experience
por: Treille, S., et al.
Publicado: (2014)

The Use of Lanreotide Autogel® in the Treatment of Intestinal Obstruction in a Patient with Adenocarcinoma
por: Lybaert, Willem
Publicado: (2014)

Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysis
por: Capdevila, Jaume, et al.
Publicado: (2015)

Correction to: Co-Creation of a Lanreotide Autogel/Depot Syringe for the Treatment of Acromegaly and Neuroendocrine Tumours Through Collaborative Human Factor Studies
por: Adelman, Daphne T., et al.
Publicado: (2020)

Real-world treatment patterns of gastrointestinal neuroendocrine tumors: A claims database analysis
por: Benson III, Al B, et al.
Publicado: (2017)

The impact of driving time, distance, and socioeconomic factors on outcomes of patients with locally advanced rectal cancer
por: Gotfrit, Joanna, et al.
Publicado: (2020)

Lessons from a multicentre retrospective study of peptide receptor radionuclide therapy combined with lanreotide for neuroendocrine tumours: a need for standardised practice
por: Prasad, Vikas, et al.
Publicado: (2020)

Differential Effects of Somatostatin, Octreotide, and Lanreotide on Neuroendocrine Differentiation and Proliferation in Established and Primary NET Cell Lines: Possible Crosstalk with TGF-β Signaling
por: Ungefroren, Hendrik, et al.
Publicado: (2022)

LanroNET, a non-interventional, prospective study to assess the resource utilization and cost of lanreotide autogel 120 mg in Polish patients with neuroendocrine tumors – results of interim analysis
por: Orlewska, Ewa, et al.
Publicado: (2014)

Efficacy of lanreotide Autogel® administered every 4–8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial
por: Lucas, T, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_v32tfqhta4smldkh79enotbdn8